期刊文献+

HPLC测定注射用头孢曲松钠他唑巴坦钠的含量及其有关物质 被引量:2

Determination of the contents and related substances of Cefriaxone sodium / Tazobactam sodium for injection by HPLC
原文传递
导出
摘要 目的采用HPLC法测定注射用头孢曲松钠他唑巴坦钠的含量及其有关物质。方法采用Kromasil C18色谱柱(250mm×4.6 mm,5μm),流动相为磷酸缓冲液-乙腈(90∶10),流速1.0 mL·min^-1,柱温30℃,检测波长230 nm。结果他唑巴坦、头孢曲松含量的线性范围分别为0.05-0.40、0.15-1.20 mg·mL^-1(r=0.9999),重复性的RSD分别为1.5%、0.5%,平均回收率分别为101.0%、100.9%,定量限分别为0.12、0.04μg;他唑巴坦、头孢曲松有关物质的线性范围分别为2.5-25.3、7.5-75.0μg·mL^-1,r分别为0.9999、0.9998,精密度的RSD分别为2.0%、0.5%,检测限分别为0.04、0.01μg,各杂质与头孢曲松及他唑巴坦两色谱峰均能完全分离。结论所用方法可用于注射用头孢曲松钠他唑巴坦钠的质量控制。 OBJECTIVE To establish an HPLC method for the determination of the contents and related substances of Cefriaxone sodium / Tazobactam sodium for injection. METHODS An Kromasil C18column( 250 mm × 4. 6 mm,5 μm) was used. The mobile phase was phosphate buffer solution- acetonitrile( 90∶10). The flow rate was 1. 0 m L·min^- 1,the column temperature was 30 ℃ and the detection wavelength was 230 nm. RESULTS In terms of contents,the caliblation curve for Tazobactam was linear in the range of0. 05 to 0. 40 mg·mL^-1( r = 0. 9999). The RSD of repeatability was 1. 5%; the average recovery was 101. 0% and the quantitative limit was 0. 12 μg. The caliblation curve for Ceftriaxone was linear in the range of 0. 15 to 1. 20 mg·mL^-1( r = 0. 9999). The RSD of precision was 0. 5%,the average recovery was 100. 9% and the quantitative limit was 0. 04 μg. In terms of related substances,the caliblation curve for Tazobactam was linear in the range of 2. 5 to 25. 3 μg·mL^-1( r = 0. 9999). The RSD of precision was 2. 0% and the detection limit was 0. 04 μg. The caliblation curve for Cefriaxone was linear in the range of 7. 5 to 75. 0 μg·mL^-1( r = 0. 9999). The RSD of precision was 0. 5% and the detection limit was 0. 01 μg. Every two peaks of each impurity with Ceftriaxone and Tazobactam could be completely separated. CONCLUSION Through the methodology validation,the method is a new reliable analytical method for the quality control of Cefriaxone sodium / Tazobactam sodium for injection.
出处 《华西药学杂志》 CAS CSCD 2016年第1期93-96,共4页 West China Journal of Pharmaceutical Sciences
关键词 注射用头孢曲松钠他唑巴坦钠 头孢曲松 他唑巴坦 高效液相色谱法 含量测定 有关物质 质量控制 Cefriaxone sodium / Tazobactam sodium for injection Cefriaxone Tazobactam HPLC Content determination Related substance Quality control
  • 相关文献

参考文献4

  • 1张守钗,陈苏婉,王晓娟,邓晓慧,孙爱慧,郑风劲,刘小康.4种配比的头孢曲松/他唑巴坦的体外抗菌活性[J].华西药学杂志,2008,23(2):143-146. 被引量:6
  • 2European Parmacopoeia 8.0 [ S ]. European directorate for the quality of medicines. Vol I . 2014 : 1815 - 1816.
  • 3British Pharmacopoeia [ S ]. British Pharmacopoeia Commision. Vol I . 2013:446 -447.
  • 4国家食品药品监督管理局标准[S].YBH04122009.

二级参考文献4

  • 1[1]Rotschafe JC,Ostergaas BE.Combination β-lactam and lacta mase-inhibitor products:amimic-robial activity and efficiency of enzyme inhibition[J].Am J Heatth-Syst Pharm,1995,52:15-23.
  • 2[3]Lister PD,Prevan AM,Sanden CC.Importance of beta-lactamase inhibitor phamacokinetics in the phamavodynamies of inhivitordrug combinations:studies with piperaeillin-tazobactam and piperacillin-sulbactam[J].Antimic Agents Chemother,1997,41:721-727.
  • 3[4]National Committee for Clinical Labarotory Stanch.Performance standards for antimicrobial susceptibility testing ninth informational supplement[M].NCCLS documents,2000.17-99.
  • 4朱延军,胡军.一种新型β-内酰胺酶抑制剂─—他佐巴坦[J].国外医药(合成药.生化药.制剂分册),1999,20(5):297-300. 被引量:13

共引文献5

同被引文献22

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部